NCT04985643 A Study of Real Life Treatment for Multiple Myeloma (MM) Status ACTIVE_NOT_RECRUITING Phase N/A
NCT04985409 Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant Status COMPLETED Phase NA
NCT04975997 Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04975555 Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04975399 Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma Status TERMINATED Phase PHASE1
NCT04960579 P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04955808 Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery Status SUSPENDED Phase N/A
NCT04942067 APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1/PHASE2
NCT04941937 Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMM Status RECRUITING Phase PHASE2
NCT04935580 Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients Status UNKNOWN Phase PHASE1/PHASE2
NCT04933539 Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04923893 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04918511 A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma Status WITHDRAWN Phase PHASE1
NCT04912427 Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease Status TERMINATED Phase PHASE1
NCT04910568 A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04898790 Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant Status RECRUITING Phase NA
NCT04895410 Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma Status TERMINATED Phase PHASE1
NCT04892446 Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma Status TERMINATED Phase PHASE2